Zacks Investment Research Lowers Checkpoint Therapeutics (CKPT) to Hold

Zacks Investment Research downgraded shares of Checkpoint Therapeutics (NASDAQ:CKPT) from a buy rating to a hold rating in a research note issued to investors on Thursday.

According to Zacks, “Checkpoint Therapeutics, Inc. is a clinical stage, immuno oncology biopharmaceutical. It focused on the acquisition, development and commercialization of non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Checkpoint Therapeutics, Inc. is headquartered in New York City. “

How to Become a New Pot Stock Millionaire

Separately, HC Wainwright began coverage on Checkpoint Therapeutics in a research report on Friday, December 8th. They issued a buy rating and a $11.00 target price on the stock.

Shares of Checkpoint Therapeutics stock opened at $4.64 on Thursday. Checkpoint Therapeutics has a 1 year low of $3.20 and a 1 year high of $13.00.

COPYRIGHT VIOLATION WARNING: This article was first reported by Ticker Report and is the property of of Ticker Report. If you are accessing this article on another domain, it was illegally copied and reposted in violation of U.S. & international copyright & trademark law. The legal version of this article can be viewed at https://www.tickerreport.com/banking-finance/3299548/zacks-investment-research-lowers-checkpoint-therapeutics-ckpt-to-hold.html.

Checkpoint Therapeutics Company Profile

Checkpoint Therapeutics, Inc is an immuno-oncology biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. The Company is engaged in developing a portfolio of human immuno-oncology targeted antibodies.

Get a free copy of the Zacks research report on Checkpoint Therapeutics (CKPT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Checkpoint Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Checkpoint Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Barrick Gold  Posts Quarterly  Earnings Results, Misses Estimates By $0.01 EPS
Barrick Gold Posts Quarterly Earnings Results, Misses Estimates By $0.01 EPS
Moelis & Company  Posts Quarterly  Earnings Results, Beats Expectations By $0.25 EPS
Moelis & Company Posts Quarterly Earnings Results, Beats Expectations By $0.25 EPS
Zacks: Brokerages Expect Apple  to Post $2.69 Earnings Per Share
Zacks: Brokerages Expect Apple to Post $2.69 Earnings Per Share
$0.26 EPS Expected for MoneyGram International Inc  This Quarter
$0.26 EPS Expected for MoneyGram International Inc This Quarter
Analyzing Target  & Its Competitors
Analyzing Target & Its Competitors
Critical Comparison: Ascena Retail Group  vs. Vince
Critical Comparison: Ascena Retail Group vs. Vince


© 2006-2018 Ticker Report. Google+.